Across TCGA pan-cancer cohorts, FSBP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FSBP data layer compared with 16 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in mesothelioma (MESO), where higher FSBP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FSBP expression acts as an unfavorable survival marker.
MESO are the cancer types where FSBP Mutation most reproducibly stratifies survival.